← All trials
NCT00656786
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Apr 1, 2008
- Primary completion
- Dec 1, 2015
- Completion date
- Dec 1, 2015
- First posted
- —
- Last posted
- —
- Enrollment
- 24
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- Spectrum PharmaceuticalsLead sponsor
- McGill UniversityOverall official - principal investigator
- Harvard UniversityOverall official - principal investigator
- Solano Clinical ResearchOverall official - principal investigator
- Northwestern UniversityOverall official - principal investigator
- Temple UniversityOverall official - principal investigator
- Washington University in St. LouisOverall official - principal investigator
- University of Texas at HoustonOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.